Last edition
News about "NOVA-2 Phase 3 schizophrenia study"
LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia
LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.
NOVA-2 Phase 3 Schizophrenia Study | 26/03/2026 | By News Bureau | 168
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members